Activities of glutathione-dependent enzymes and glucose-6-phosphate dehydrogenase (GPDH) were studied in blood of the patients with lymphosarcoma (LS). The activity of glutathione reductase (GR), glutathione dehydroascorbate reductase (GDAR), gamma-glutamyltranspeptidase (GGT) and G6PDH in plasma, leucocytes, lymphocytes and erythrocytes of peripheral blood in 30 patients (42-56 years) with LS and in 20 healthy have been determined with spectrophotometric methods (Humalyzer 2000 DE). Leucocytes and lymphocytes were separated from blood using Boyum method. Spearmen method used for correlative analysis. The levels of enzymes activity and results of correlative analysis showed an imbalance of antioxidative system defense and metabolic disturbances in patients with LS. The strong functional interrelation was estimated only between GR and G6PDH in the patients' lymphocytes (r=+0,716; p<0.0005). Interrelation was found between the levels of activity of antioxidative enzymes and activity (stage) of pathologic process, this may be used as the additional biochemical test for differential diagnostics of LS and estimation of the cells proliferative activity.
Background: Non-Hodgkin’s lymphomas (NHL) are malignant tumors that develop from lymphoid tissue. Primary lymph node (LN) involvement is the most common localization (52-70%). The integration of Rituximab (R) in the NHL treatment represented a turning point. The aim of this study was to evaluate the therapeutic impact of the use of R in combination with conventional polychemotherapeutic (PChT) in the treatment of nodal onset NHL. Material and methods: A descriptive cohort study was performed on 80 patients diagnosed with NHL. Results: In the study participated: men – 39(48.8%), women – 41(51.2%). The mean age of the patients was 56.09 ± 13.6 years. The onset of NHL occurred in peripheral l/n in 85.0% of cases, in mediastinal LN – 7.5%, and abdominals in 7.5%. Stages I-II were identified in 21(26.2%) patients, stages III-IV in 59(73.8%) cases. Aggressive NHLs were diagnosed in 54(67.5%) patients, indolent NHLs in 26(32.5%) cases. In 61(76.3%) patients, first-line R+PChT treatment was applied – group 1(G1), and in 19(23.8%) cases conventional PChT was applied – group 2(G2). The overall response rate (ORR) in G1 was 86.8%, in G2 – 63.1%. Complete remissions (CR) were obtained in G1 in 63.9% of patients, in G2 – 47.3% of cases. Progression-free survival (PFS) in G1 had a median of 20 months, and in G2 the median was 12 months (p <0.05). Conclusions: The use of Rituximab increased the ORR rate (86.8% vs 63.1%), the frequency of CR (63.9% vs 47.3%) and PFS (20 months vs 12 months (p <0.05).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.